SRRK Long Call Strategy
SRRK (Scholar Rock Holding Corporation), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
SRRK (Scholar Rock Holding Corporation) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $6.01B, a beta of 0.71 versus the broader market, a 52-week range of 27.07-51.625, average daily share volume of 1.5M, a public-listing history dating back to 2018, approximately 128 full-time employees. These structural characteristics shape how SRRK stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.71 places SRRK roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a long call on SRRK?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current SRRK snapshot
As of May 15, 2026, spot at $49.16, ATM IV 51.90%, IV rank 11.33%, expected move 14.88%. The long call on SRRK below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long call structure on SRRK specifically: SRRK IV at 51.90% is on the cheap side of its 1-year range, which favors premium-buying structures like a SRRK long call, with a market-implied 1-standard-deviation move of approximately 14.88% (roughly $7.31 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SRRK expiries trade a higher absolute premium for lower per-day decay. Position sizing on SRRK should anchor to the underlying notional of $49.16 per share and to the trader's directional view on SRRK stock.
SRRK long call setup
The SRRK long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SRRK near $49.16, the first option leg uses a $49.16 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SRRK chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SRRK shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $49.16 | N/A |
SRRK long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
SRRK long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on SRRK. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on SRRK
Long calls on SRRK express a bullish thesis with defined risk; traders use them ahead of SRRK catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
SRRK thesis for this long call
The market-implied 1-standard-deviation range for SRRK extends from approximately $41.85 on the downside to $56.47 on the upside. A SRRK long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current SRRK IV rank near 11.33% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on SRRK at 51.90%. As a Healthcare name, SRRK options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SRRK-specific events.
SRRK long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SRRK positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SRRK alongside the broader basket even when SRRK-specific fundamentals are unchanged. Long-premium structures like a long call on SRRK are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current SRRK chain quotes before placing a trade.
Frequently asked questions
- What is a long call on SRRK?
- A long call on SRRK is the long call strategy applied to SRRK (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With SRRK stock trading near $49.16, the strikes shown on this page are snapped to the nearest listed SRRK chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are SRRK long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the SRRK long call priced from the end-of-day chain at a 30-day expiry (ATM IV 51.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a SRRK long call?
- The breakeven for the SRRK long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SRRK market-implied 1-standard-deviation expected move is approximately 14.88%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on SRRK?
- Long calls on SRRK express a bullish thesis with defined risk; traders use them ahead of SRRK catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current SRRK implied volatility affect this long call?
- SRRK ATM IV is at 51.90% with IV rank near 11.33%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.